These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 35633275

  • 1. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.
    Vinckenbosch F, Asin J, de Vries N, Vonk PE, Donjacour CEHM, Lammers GJ, Overeem S, Janssen H, Wang G, Chen D, Carter LP, Zhou K, Vermeeren A, Ramaekers JG.
    Hum Psychopharmacol; 2022 Nov; 37(6):e2845. PubMed ID: 35633275
    [Abstract] [Full Text] [Related]

  • 2. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK, Mayer G, Rosenberg R, Malhotra A, Zammit GK, Gotfried M, Chandler P, Baladi M, Strohl KP.
    Chest; 2021 Jul; 160(1):307-318. PubMed ID: 33631141
    [Abstract] [Full Text] [Related]

  • 3. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM.
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [Abstract] [Full Text] [Related]

  • 4. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
    Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP, TONES 3 Study Investigators.
    Am J Respir Crit Care Med; 2019 Jun 01; 199(11):1421-1431. PubMed ID: 30521757
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK.
    Sleep Med; 2020 Nov 01; 75():510-521. PubMed ID: 33032062
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Ronnebaum S, Bron M, Patel D, Menno D, Bujanover S, Kratochvil D, Lucas E, Stepnowsky C.
    J Clin Sleep Med; 2021 Dec 01; 17(12):2543-2555. PubMed ID: 34402784
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.
    Schweitzer PK, Strohl KP, Mayer G, Rosenberg R, Chandler P, Baladi M, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Apr 01; 17(4):659-668. PubMed ID: 33179591
    [Abstract] [Full Text] [Related]

  • 13. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
    Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG, Andry JM, Hudson JD, Chen D, Carter LP, Bron M, Lee L, Black J, Bogan RK.
    Ann Am Thorac Soc; 2020 Aug 01; 17(8):998-1007. PubMed ID: 32353246
    [Abstract] [Full Text] [Related]

  • 14. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ, Hedner J, Collop N, Lorch DG, Chen D, Carter LP, Lu Y, Lee L, Black J, Pépin JL, Redline S, Tones 4 Study Investigators.
    Chest; 2019 Feb 01; 155(2):364-374. PubMed ID: 30471270
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC, Sheehan AH, Jordan JK.
    J Pharm Pract; 2022 Dec 01; 35(6):963-970. PubMed ID: 33882756
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA.
    Mov Disord; 2021 Oct 01; 36(10):2408-2412. PubMed ID: 34191352
    [Abstract] [Full Text] [Related]

  • 20. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
    Powell J, Piszczatoski C, Garland S.
    Ann Pharmacother; 2020 Oct 01; 54(10):1016-1020. PubMed ID: 32270686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.